Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapamycin Responds to Alzheimer’s Disease: A Potential Translational Therapy

1 Oct 2023

Abstract excerpt

Abstract: Alzheimer’s disease (AD) is a sporadic or familial neurodegenerative disease of insidious onset with progressive cognitive decline. Although numerous studies have been conducted or are underway on AD, there are still no effective drugs to reverse the pathological features and clinical manifestations of AD. Rapamycin is a macrolide antibiotic produced by Streptomyces hygroscopicus . As a classical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Cholinesterase and Neurodegenerative Diseases
Share to Genetics, Aging, and Longevity in Model Organisms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37810956
DOI: 10.2147/cia.s429440

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapamycin Responds to Alzheimer’s Disease: A Potential Translational TherapyPMID 37810956Read ↗

Taking aim at Alzheimer's disease through the mammalian target of rapamycinSemantic proximity Read ↗

Small Molecule Enhancers of Rapamycin-Induced TOR Inhibition Promote Autophagy, Reduce Toxicity in Huntington’s Disease Models and Enhance Killing of Mycobacteria by MacrophagesSemantic proximity Read ↗

Evaluating the effect of rapamycin treatment in Alzheimer's Disease and aging using<i>in vivo</i>imaging: the ERAP phase IIa clinical study protocolSemantic proximity Read ↗

Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disordersSemantic proximity Read ↗

Methyllycaconitine Alleviates Amyloid-β Peptides-Induced Cytotoxicity in SH-SY5Y CellsSemantic proximity Read ↗

Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both β-amyloid production and clearance.Semantic proximity Read ↗

Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer’s Disease and DiabetesSemantic proximity Read ↗

Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegenerationSemantic proximity Read ↗

A drug cocktail of rapamycin, acarbose, and phenylbutyrate enhances resilience to features of early-stage Alzheimer’s disease in aging miceSemantic proximity Read ↗

Anti-autophagic and anti-apoptotic effects of memantine in a SH-SY5Y cell model of Alzheimer's disease via mammalian target of rapamycin-dependent and -independent pathways.Semantic proximity Read ↗

Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice.Semantic proximity Read ↗

The Role of mTOR Signaling in Controlling Mammalian Life Span: What a Fungicide Teaches Us About LongevitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.